Hovedundersøgelsen af pancreascancer omfattede 569 patienter med fremskreden inoperabel (umulig at fjerne kirurgisk) eller metastatisk pancreascancer i kombination med gemcitabin.
The main study in pancreatic cancer involved 569 patients with advanced, unresectable (unable to be removed by surgery) or metastatic pancreatic cancer, in combination with gemcitabine.